Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04746625

Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment

Status
Recruiting
Phase
Study type
Observational
Enrollment
126 (estimated)
Sponsor
Sophysa · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The SAPPHYRE study is an ambispective (retrospective and prospective) PMCF study with the objective to evaluate the safety and performance of the Polaris® 24 adjustable valve system in the treatment of 126 patients with hydrocephalus.

Detailed description

The SAPPHYRE study is an ambispective (retrospective and prospective), non-interventional, multicenter, post-market clinical follow-up study. The study objective is to evaluate the safety and performance of Sophysa's CE marked Polaris® 24 adjustable valve system in the treatment of hydrocephalus by shunting the cerebrospinal fluid. It is expected to recruit 126 patients in two-year. Patients will be followed-up up to 5 years post-procedure.

Conditions

Timeline

Start date
2021-06-04
Primary completion
2029-06-01
Completion
2033-06-01
First posted
2021-02-10
Last updated
2026-01-27

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04746625. Inclusion in this directory is not an endorsement.

Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment (NCT04746625) · Clinical Trials Directory